SFA Therapeutics Inc. Requests FDA Orphan Drug Designation ODD for SFA001 for Treatment of Hepatocellular Carcinoma HCC

SFA Therapeutics Inc. announced today that the company has filed an FDA application requesting Orphan Drug Designation ODD for SFA001 the companys novel microbiomebased treatment for human hepatocellular carcinoma HCC.In seeking Orphan Drug Designation ODD...